ReviewFrontiers in immunology2013
HLA-DO and Its Role in MHC Class II Antigen Presentation.
Review in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- Advancements in HLA Typing Techniques and Their Impact on Transplantation Medicine.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024Review
- Global and cell type-specific immunological hallmarks of severe dengue progression identified via a systems immunology approach.Nature immunology · 2023Article
- MHC Class II Presentation in Autoimmunity.Cells · 2023Review
- H2-O deficiency promotes regulatory T cell differentiation and CD4 T cell hyperactivity.Frontiers in immunology · 2023Article
- A guide to antigen processing and presentation.Nature reviews. Immunology · 2022Review
- A Morbillivirus Infection Shifts DC Maturation Toward a Tolerogenic Phenotype to Suppress T Cell Activation.Journal of virology · 2022Article
- Pan-Cancer HLA Gene-Mediated Tumor Immunogenicity and Immune Evasion.Molecular cancer research : MCR · 2022Article
- MUC22, HLA-A, and HLA-DOB variants and COVID-19 in resilient super-agers from Brazil.Frontiers in immunology · 2022Article
- Blood transcriptomics to characterize key biological pathways and identify biomarkers for predicting mortality in melioidosis.Emerging microbes & infections · 2021Article
- Partnering for the major histocompatibility complex class II and antigenic determinant requires flexibility and chaperons.Current opinion in immunology · 2021Review
- How Does B Cell Antigen Presentation Affect Memory CD4 T Cell Differentiation and Longevity?Frontiers in immunology · 2021Review
- Gene-Based Tests of a Genome-Wide Association Study Dataset Highlight Novel Multiple Sclerosis Risk Genes.Frontiers in neuroscience · 2021Article
- High MHC-II expression in Epstein-Barr virus-associated gastric cancers suggests that tumor cells serve an important role in antigen presentation.Scientific reports · 2020Article
- Characterization of two MHC II genes (DOB, DRB) in white-tailed deer (Odocoileus virginianus).BMC genetics · 2020Article
- How a Proposed Hypothesis during My PhD Training Shaped My Career.Critical reviews in immunology · 2020Article
- Selection of immunodominant epitopes during antigen processing is hierarchical.Molecular immunology · 2019Review
- Article
- Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Review
- Structural aspects of chaperone-mediated peptide loading in the MHC-I antigen presentation pathway.Critical reviews in biochemistry and molecular biology · 2019Review
- What to do with HLA-DO/H-2O two decades later?Immunogenetics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Helper T cells are stimulated to fight infections or diseases upon recognition of peptides from antigens that are processed and presented by the proteins of Major Histocompatibility Complex (MHC) Class II molecules. Degradation of a full protein into small peptide fragments is a lengthy process consisting of many steps and chaperones. Malfunctions during any step of antigen processing could lead to the development of self-reactive T cells or defective immune response to pathogens. Although much has been accomplished regarding how antigens are processed and presented to T cells, many questions still remain unanswered, preventing the design of therapeutics for direct intervention with antigen processing. Here, we review published work on the discovery and function of a MHC class II molecular chaperone, HLA-DO, in human, and its mouse analog H2-O, herein called DO. While DO was originally discovered decades ago, elucidating its function has proven challenging. DO was discovered in association with another chaperone HLA-DM (DM) but unlike DM, its distribution is more tissue specific, and its function more subtle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.